High-grade Serous Ovarian Carcinoma (HGSOC)AI-PTHGSOCNCT07721675
Artificial Intelligence-guided Precision Treatment of High-grade Serous Ovarian Carcinoma
An observational study of High-grade Serous Ovarian Carcinoma (HGSOC), run by The Affiliated Hospital of Qingdao University.
Trial summary
The subjects of this study are patients with high-grade serous ovarian cancer who have undergone surgical resection. The aim is to construct an artificial intelligence model for predicting postoperative recurrence, metastasis and overall survival of patients based on multimodal data such as surgical pathological… Read more about this study
- Who is it for?
- Ages 18 to 80 years, women only
- Conditions the study is for
- High-grade Serous Ovarian Carcinoma (HGSOC)
- How many people
- 1,300 participants
- Where
- No sites listed yet
- Study dates
- 1 Aug 2026to 31 Dec 2027
- Phase
- Observational
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 to 80 years
- Women only
- No healthy volunteers
- Adult, Older adult
Study population: Patients with histologically confirmed high-grade serous ovarian carcinoma (HGSOC)
Who may be able to join
- Histologically confirmed high-grade serous ovarian carcinoma using resection specimens.
- Well-preserved surgical paraffin-embedded tumor specimens.
- Complete clinical information and survival follow-up data.
Who cannot join
- Received preoperative neoadjuvant treatment.
- Poor preservation of surgical paraffin specimens.
- Incomplete clinical information and survival follow-up data.
- With concurrent malignancies other than high-grade serous ovarian carcinoma.
Trial locations and contacts
No sites are listed yet. Contact the study team or a site near you to ask about taking part.
About this study
Official title: Personalized Precision Diagnosis and Treatment of High-grade Serous Ovarian Carcinoma During the Perioperative Period Assisted by Multi-omics and Artificial Intelligence Models, and Research on the Heterogeneity of Immune Microenvironment
The subjects of this study are patients with high-grade serous ovarian cancer who have undergone surgical resection. The aim is to construct an artificial intelligence model for predicting postoperative recurrence, metastasis and overall survival of patients based on multimodal data such as surgical pathological images (HE images and IHC images of immune microenvironment-related markers), preoperative baseline imaging data and detailed clinical information of patients. In addition, multi-omics sequencing analysis will be used to deeply explore the heterogeneity of the tumor microenvironment, with the expectation of quantifying the postoperative recurrence risk of patients with high-grade serous ovarian cancer and providing new ideas for the precise diagnosis and treatment of patients with high-grade serous ovarian cancer.
- Being tested
- No Intervention: Observational Cohort
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
No Intervention: Observational CohortOther
This study is an retrospective observational study. There will be no interventions on the participants.
| Study group | Role | What they receive |
|---|---|---|
| High-Risk Group of Recurrence or Metastasis | AI-assisted patients who have high-risk of postoperative recurrence or metastasis. Receives: Other: No Intervention: Observational Cohort | |
| Low-Risk Group of Recurrence or Metastasis | AI-assisted patients who have low-risk of postoperative recurrence or metastasis. Receives: Other: No Intervention: Observational Cohort |
What is being measured
The primary outcome is the main question the study is designed to answer.
Disease-free survival
Measured: through study completion, an average of 1 year
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted23 Jul 2026
- Study start1 Aug 2026 (estimated)
- Primary completion31 Mar 2027 (estimated)
- Study completion31 Dec 2027 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for High-grade Serous Ovarian Carcinoma (HGSOC)Studies of the same condition, open and under way.
- More trials run by The Affiliated Hospital of Qingdao UniversityThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Cohort
- Time perspective
- Retrospective
- Enrolment
- 1,300 participants (estimated)
Sponsor and investigators
- Lead sponsor
- The Affiliated Hospital of Qingdao University
- Sponsor type
- University, hospital or other
- Collaborators
- Shandong Provincial Hospital, Yantai Yuhuangding Hospital, Peking University Third Hospital
- Responsible party
- Sponsor
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07721675
- Sponsor's protocol ID
- QYFYEC2025-365
- Acronym
- AI-PTHGSOC
- Status last verified
- Jul 2026
- First submitted
- 19 Jul 2026
- Last updated
- 23 Jul 2026
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No
Study at a glance
From the registry record, last updated by the sponsor on 23 Jul 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Personalized Precision Diagnosis and Treatment of High-grade Serous Ovarian Carcinoma During the Perioperative Period Assisted by Multi-omics and Artificial Intelligence Models, and Research on the Heterogeneity of Immune Microenvironment
- ClinicalTrials.gov ID
- NCT07721675
- Acronym / sponsor ID
- AI-PTHGSOC / QYFYEC2025-365
- Study type
- Observational
- Recruitment status
- Not yet recruiting
- Enrolment
- 1,300 participants (estimated)
- Lead sponsor
- The Affiliated Hospital of Qingdao UniversityUniversity, hospital or other
- Collaborators
- Shandong Provincial Hospital, Yantai Yuhuangding Hospital, Peking University Third Hospital
- Study start
- 1 Aug 2026 (estimated)
- Primary completion
- 31 Mar 2027 (estimated)
- Study completion
- 31 Dec 2027 (estimated)
- First posted
- 23 Jul 2026 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The subjects of this study are patients with high-grade serous ovarian cancer who have undergone surgical resection. The aim is to construct an artificial intelligence model for predicting postoperative recurrence, metastasis and overall survival of patients based on multimodal data such as surgical pathological images (HE images and IHC images of immune microenvironment-related markers), preoperative baseline imaging data and detailed clinical information of patients. In addition, multi-omics sequencing analysis will be used to deeply explore the heterogeneity of the tumor microenvironment, with the expectation of quantifying the postoperative recurrence risk of patients with high-grade serous ovarian cancer and providing new ideas for the precise diagnosis and treatment of patients with high-grade serous ovarian cancer.
Study design
- Observational model
- Cohort
- Time perspective
- Retrospective
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| High-Risk Group of Recurrence or Metastasis | – | Other: No Intervention: Observational CohortAI-assisted patients who have high-risk of postoperative recurrence or metastasis. |
| Low-Risk Group of Recurrence or Metastasis | – | Other: No Intervention: Observational CohortAI-assisted patients who have low-risk of postoperative recurrence or metastasis. |
Who may qualify
- Ages
- 18 to 80 years
- Sex
- Female only
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
- Study population
- Patients with histologically confirmed high-grade serous ovarian carcinoma (HGSOC)
Key inclusion criteria (3 listed)
- Histologically confirmed high-grade serous ovarian carcinoma using resection specimens.
- Well-preserved surgical paraffin-embedded tumor specimens.
- Complete clinical information and survival follow-up data.
Key exclusion criteria (4 listed)
- Received preoperative neoadjuvant treatment.
- Poor preservation of surgical paraffin specimens.
- Incomplete clinical information and survival follow-up data.
- With concurrent malignancies other than high-grade serous ovarian carcinoma.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| No Intervention: Observational CohortThis study is an retrospective observational study. There will be no interventions on the participants. | Other | High-Risk Group of Recurrence or Metastasis, Low-Risk Group of Recurrence or Metastasis |
Primary outcome
Disease-free survival
Time frame: through study completion, an average of 1 year
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 23 Jul 2026.
- Individual participant dataSharing planned: No
Related trials for High-grade Serous Ovarian Carcinoma (HGSOC)
RecruitingPhase 2
Neoadjuvant Aitua (PD-1/CTLA-4 Bispecific) Plus Nab-Paclitaxel and Carboplatin for Advanced High-Grade Serous Ovarian Cancer
High-grade Serous Ovarian Cancer (HGSOC), Fallopian Tube Cancers
Active, not recruiting
68Ga-FAPI PET/CT in the Staging of High-Grade Epithelial Ovarian Cancers: A Pilot Study
High Grade Serous Ovarian Cancer (HGSOC)
Active, not recruitingPhase 1/2
A First-in-human Dose Escalation and Expansion Study to Evaluate the Safety, and Tolerability of AZD8421 Alone or in Combination in Participants With Selected Advanced or Metastatic Solid Tumors
ER+ HER2- Advanced Breast Cancer, High-grade Serous Ovarian Cancer (HGSOC)
Recruiting
OV Precision: Study Examining the Benefit of a Tumor- and Patient-specific Cancer Therapy
Ovarian Neoplasm Epithelial, Fallopian Tube Neoplasms
RecruitingPhase 1
Study of CryptiVax-1001 in Maintenance Setting for Advanced Serous Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
Ovarian Cancer, HGSOC
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
Questions about this trial
What is this clinical trial studying?
An observational study of High-grade Serous Ovarian Carcinoma (HGSOC), run by The Affiliated Hospital of Qingdao University.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 3 inclusion and 4 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: opening soon, as of the sponsor's last update on 23 Jul 2026. Status can change between updates, so confirm with the study contact before making plans.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Contact Xiaoming Xing (+8653282911869, edithxing@126.com), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Disease-free survival (time frame: through study completion, an average of 1 year). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 23 Jul 2026.